The two companies have created the platform that combines adherence and lung function measurement with medication management services.
The company's connected devices and mobile apps engage and empower respiratory patients by measuring lung function and tracking adherence.
The four-year grant is part of a national $144 million initiative called Pediatric Research using Integrated Sensor Monitoring Systems or PRISMS.
GSK will use the sensor in the studies to automatically collect and record data on the inhaler's usage, and wirelessly transmit the data collected.
The device will monitor air quality, CO2 levels in the blood, physical activity, breathing, emotional states and other stimuli to identify asthma triggers.
Featuring medical-grade accuracy, the device has been launched on crowdfunding website Indiegogo, with the goal of raising $50,000 in a month-long campaign.
Called My Asthma Pal, the application runs of iOS and Android devices, providing children and their parents with a mobile tool to track and manage asthma.
Also the three studies Adherium has conducted have found a 14.9% increase in lung function and a 37% reduction in oral steroid usage.
Said app enables asthma patients to participate in a study by using their iPhones; the new features enable participants to use the app with their physicians.
FDA-approved marketing claims of improved adherence and reduction in exacerbations address key unmet needs in respiratory health.